CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)

PRESS RELEASE AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency ...
Hosted on MSN

Study shows targeting non-cancerous cells can overcome ovarian cancer resistance

In a recent paper published in Nature, researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase (NNMT), an enzyme that is involved in the progression of ...
WKRG

NCC-Bio to Present Strategy to Overcome KRAS Inhibitor Resistance at RAS Summit in Boston

Visit the Session in upcoming 7th RAS-Targeted Drug Development Summit, Boston, Sept 16–18, 2025, Session: Sept.17, Thursday. Or, Call 978-269-4198 (m), Warren Park for in-person meetings! KN510713, ...
Medical Xpress

Dual studies uncover complementary strategies to overcome resistance to KRAS G12C inhibitors in lung cancer

Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C-mutant non-small ...
Medical Xpress

Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in ...
News Medical

Studies identify complementary approaches to overcome drug resistance in KRAS G12C–mutant lung cancer

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...